{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:24:09Z","timestamp":1790627049626,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T00:00:00Z","timestamp":1388793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00223-013-9835-2","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:25:18Z","timestamp":1388708718000},"page":"608-612","source":"Crossref","is-referenced-by-count":19,"title":["Follow-Up of Six Patients with Neurofibromatosis 1-Related Osteoporosis Treated with Alendronate for 23 Months"],"prefix":"10.1007","volume":"94","author":[{"given":"Eetu","family":"Heerv\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huilaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkku","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Peltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,4]]},"reference":[{"key":"9835_CR1","volume-title":"Neurofibromatosis: phenotype, natural history and pathogenesis","author":"V Riccardi","year":"1986","unstructured":"Riccardi V, Eichner J (1986) Neurofibromatosis: phenotype, natural history and pathogenesis. Johns Hopkins University Press, Baltimore"},{"key":"9835_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000126500","volume-title":"Neurofibromatoses","author":"S Huson","year":"2008","unstructured":"Huson S (2008) The neurofibromatoses: classification, clinical features and genetic counseling. In: Kaufmann D (ed) Neurofibromatoses. Monographs in human genetics, Karger, pp 1\u201320"},{"key":"9835_CR3","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.ajpath.2010.12.056","volume":"178","author":"EM Jouhilahti","year":"2011","unstructured":"Jouhilahti EM, Peltonen S, Heape A, Peltonen J (2011) Pathoetiology of neurofibromatosis. Am J Pathol 178:1932\u20131939","journal-title":"Am J Pathol"},{"key":"9835_CR4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","volume":"62","author":"G Xu","year":"1990","unstructured":"Xu G, O\u2019Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599\u2013608","journal-title":"Cell"},{"key":"9835_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"D Stumpf","year":"1988","unstructured":"Stumpf D, Annergers J, Brown S, Conneally P, Housman D, Leppert M, Miller J, Moss M, Pileggi A, Rapin I, Strohman R, Swanson L, Zimmersman A (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575\u2013578","journal-title":"Arch Neurol"},{"key":"9835_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-642-32864-0_2","volume-title":"Neurofibromatosis type 1: molecular and cellular biology","author":"S Peltonen","year":"2012","unstructured":"Peltonen S, Poyhonen M (2012) Clinical diagnosis and atypical forms of NF1. In: Upadhyaya M, Cooper D (eds) Neurofibromatosis type 1: molecular and cellular biology. Springer, Berlin, pp 17\u201330"},{"key":"9835_CR7","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ajmg.a.33045","volume":"149","author":"F Elefteriou","year":"2009","unstructured":"Elefteriou F, Kolanczyk M, Schindeler A et al (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149:2327\u20132338","journal-title":"Am J Med Genet A"},{"key":"9835_CR8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00198-004-1801-4","volume":"16","author":"T Kuorilehto","year":"2005","unstructured":"Kuorilehto T, P\u00f6yh\u00f6nen M, Bloigu R, Heikkinen J, V\u00e4\u00e4n\u00e4nen K, Peltonen J (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928\u2013936","journal-title":"Osteoporos Int"},{"key":"9835_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri N, Doty S, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis R, Plon S, Phillips W, O\u2019Brian Smith E, Ellis K, Lee B (2008) Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab 94:105\u2013111","journal-title":"Mol Genet Metab"},{"key":"9835_CR10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jmg.2008.061895","volume":"46","author":"T Tucker","year":"2009","unstructured":"Tucker T, Schnabel C, Hartmann M, Friedrich R, Frieling I, Kruse H, Mautner V, Friedman J (2009) Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 46:259\u2013265","journal-title":"J Med Genet"},{"key":"9835_CR11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00403-011-1191-3","volume":"304","author":"L Petramala","year":"2012","unstructured":"Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G, Formicuccia M, D\u2019Erasmo E, Calvieri S, Letizia C (2012) Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklinghausen disease). Arch Dermatol Res 304:325\u2013331","journal-title":"Arch Dermatol Res"},{"key":"9835_CR12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2011.12.011","volume":"50","author":"E Heerv\u00e4","year":"2012","unstructured":"Heerv\u00e4 E, Peltonen S, Svedstr\u00f6m E, Aro HT, V\u00e4\u00e4n\u00e4nen K, Peltonen J (2012) Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone 50:798\u2013803","journal-title":"Bone"},{"key":"9835_CR13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00223-012-9661-y","volume":"92","author":"E Heerv\u00e4","year":"2013","unstructured":"Heerv\u00e4 E, Leinonen P, Kuorilehto T, Peltonen S, P\u00f6yh\u00f6nen M, V\u00e4\u00e4n\u00e4nen K, Peltonen J (2013) Neurofibromatosis 1\u2013related osteopenia often progresses to osteoporosis in 12\u00a0years. Calcif Tissue Int 92:23\u201327","journal-title":"Calcif Tissue Int"},{"key":"9835_CR14","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/jbmr.1685","volume":"27","author":"E Heerv\u00e4","year":"2012","unstructured":"Heerv\u00e4 E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, Aro HT, Peltonen J (2012) A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41\u00a0years of age. J Bone Miner Res 27:2333\u20132337","journal-title":"J Bone Miner Res"},{"key":"9835_CR15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajmg.a.35541","volume":"161","author":"J George-Abraham","year":"2013","unstructured":"George-Abraham J, Martin L, Kalkwarf H, Rieley M, Stevenson D, Viskochil D, Hopkin R, Stevens A, Hanson H, Schorry E (2013) Fractures in children with neurofibromatosis type 1 from two NF clinics. Am J Med Gen A 161:921\u2013926","journal-title":"Am J Med Gen A"},{"key":"9835_CR16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"9835_CR17","first-page":"1078","volume":"19","author":"E Lewiecki","year":"2008","unstructured":"Lewiecki E, Gordon C, Baim S, Binkley N, Bilezikian J, Kendler D, Hans D, Silverman S, Bishop N, Leonard M, Bianchi M, Kalkwarf H, Langman C, Plotkin H, Rauch F, Zemel B (2008) Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos Int 19:1078\u20131369","journal-title":"Osteoporos Int"},{"key":"9835_CR18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","volume":"373","author":"J Bergstrom","year":"2000","unstructured":"Bergstrom J, Bostedor R, Masarachia P, Reszka A, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231\u2013234","journal-title":"Arch Biochem Biophys"},{"key":"9835_CR19","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","volume":"21","author":"J Dunford","year":"2006","unstructured":"Dunford J, Rogers M, Ebetino F, Phipps R, Coxon F (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684\u2013694","journal-title":"J Bone Miner Res"},{"key":"9835_CR20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","volume":"87","author":"S Gallacher","year":"2010","unstructured":"Gallacher S, Dixon T (2010) Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int 87:469\u2013484","journal-title":"Calcif Tissue Int"},{"key":"9835_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11587570-000000000-00000","volume":"71","author":"J Reginster","year":"2011","unstructured":"Reginster J (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65\u201378","journal-title":"Drugs"},{"key":"9835_CR22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O, Foldes A, Garnero P, Griesmacher A, McClung M, Morris H, Silverman S, Trenti T, Wahl D, Cooper C, Kanis J (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391\u2013420","journal-title":"Osteoporos Int"},{"key":"9835_CR23","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"S Cummings","year":"1998","unstructured":"Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T, Palermo L, Prineas R, Rubin S, Scott J, Vogt T, Wallace R, Yates A, LaCroix A (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"9835_CR24","first-page":"3109","volume":"85","author":"R Tonino","year":"2000","unstructured":"Tonino R, Meunier P, Emkey R, Rodriguez-Portales J, Menkes C, Wasnich R, Bone H, Santora A, Wu M, Desai R, Ross P (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109\u20133115","journal-title":"J Clin Endocrinol Metab"},{"key":"9835_CR25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"H Bone","year":"2004","unstructured":"Bone H, Hosking D, Devogelaer J, Tucci J, Emkey R, Tonino R, Rodriguez-Portales J, Downs R, Gupta J, Santora A, Liberman U (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"9835_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"C Rosen","year":"2005","unstructured":"Rosen C, Hochberg M, Bonnick S, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke R, Thompson D, de Papp A (2005) Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141\u2013151","journal-title":"J Bone Miner Res"},{"key":"9835_CR27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","volume":"20","author":"A Nenonen","year":"2005","unstructured":"Nenonen A, Cheng S, Ivaska K, Alatalo S, Lehtim\u00e4ki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Siev\u00e4nen H, Vuori I, V\u00e4\u00e4n\u00e4nen K, Halleen J (2005) Serum TRAP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804\u20131812","journal-title":"J Bone Miner Res"},{"key":"9835_CR28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11832-010-0293-3","volume":"4","author":"O Birke","year":"2010","unstructured":"Birke O, Schindeler A, Ramachandran M, Cowell C, Munns C, Bellemore M, Little D (2010) Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia. J Child Orthop 4:507\u2013517","journal-title":"J Child Orthop"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-013-9835-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-013-9835-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-013-9835-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T07:41:09Z","timestamp":1558683669000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-013-9835-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9835"],"URL":"https:\/\/doi.org\/10.1007\/s00223-013-9835-2","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,4]]}}}